Daiwa Securities Group Inc. Buys 110 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Daiwa Securities Group Inc. raised its position in iShares Biotechnology ETF (NASDAQ:IBB) by 12.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,028 shares of the financial services provider’s stock after buying an additional 110 shares during the quarter. Daiwa Securities Group Inc.’s holdings in iShares Biotechnology ETF were worth $150,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Commerce Bank grew its holdings in shares of iShares Biotechnology ETF by 1.8% during the 3rd quarter. Commerce Bank now owns 743,366 shares of the financial services provider’s stock valued at $108,234,000 after purchasing an additional 12,921 shares during the last quarter. Main Management ETF Advisors LLC lifted its position in shares of iShares Biotechnology ETF by 2.6% during the 2nd quarter. Main Management ETF Advisors LLC now owns 578,835 shares of the financial services provider’s stock valued at $79,451,000 after acquiring an additional 14,535 shares during the period. Raymond James Financial Services Advisors Inc. raised its holdings in shares of iShares Biotechnology ETF by 24.6% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 217,047 shares of the financial services provider’s stock valued at $29,792,000 after purchasing an additional 42,822 shares during the period. Raymond James & Associates boosted its holdings in iShares Biotechnology ETF by 4.4% in the second quarter. Raymond James & Associates now owns 189,766 shares of the financial services provider’s stock worth $26,047,000 after acquiring an additional 7,931 shares in the last quarter. Finally, Albion Financial Group UT lifted its holdings in shares of iShares Biotechnology ETF by 0.3% in the 3rd quarter. Albion Financial Group UT now owns 129,980 shares of the financial services provider’s stock worth $18,925,000 after purchasing an additional 356 shares in the last quarter. 62.45% of the stock is owned by institutional investors.

iShares Biotechnology ETF Trading Down 0.0 %

IBB stock opened at $141.55 on Monday. iShares Biotechnology ETF has a 52-week low of $119.95 and a 52-week high of $150.57. The business has a 50-day simple moving average of $142.71 and a two-hundred day simple moving average of $142.06.

iShares Biotechnology ETF Announces Dividend

The company also recently announced a dividend, which was paid on Monday, September 30th. Shareholders of record on Wednesday, September 25th were given a $0.2005 dividend. The ex-dividend date of this dividend was Wednesday, September 25th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.